Goldman Sachs
RNAZ icon

Goldman Sachs’s TransCode Therapeutics RNAZ Stock Holding History

Goldman Sachs’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,042
Closed -$219K – 6611
2025
Q2 		$219K Buy
+28,042
New +$260K ﹤0.01% 5615
2023
Q2 		– Hold
0
– -$4.44K – 6018
2023
Q1 		– Hold
0
– – – 5802
2022
Q4 		– Hold
0
– – – 5742

Other funds holding RNAZ

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs's RNAZ Position: Q3 2025 in Review

Goldman Sachs sold out of TransCode Therapeutics (RNAZ) in Q3 2025, closing a stake of 28,042 shares — an estimated $219K sold.

Goldman Sachs first reported a position in RNAZ in Q2 2025 and held it in 1 quarter. The position peaked at $219K in Q2 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q3 2025.

  • Goldman Sachs reported no remaining TransCode Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 28,042 TransCode Therapeutics shares in Q3 2025, an estimated $219K.
  • Goldman Sachs first reported a position in TransCode Therapeutics in Q2 2025 and held it in 1 quarter.
  • Goldman Sachs's TransCode Therapeutics position peaked at $219K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.